Loading
Zydus Lifesciences Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Jasodaben Babubhai Patel, was filed 14 Nov 2025.
Insider Decl.
96
Thresholds
n/a
Buy Volume
€278,512
6 ops. · all time
Sell Volume
€7M
13 ops. · all time
Who traded when
BuySaleJasodaben Babubhai Patel1 buy
Since the insiders bought
- +20.1%Entry ₹934.75 · Close 16 Oct 2026 ₹1,123.00
- +32.8%Entry ₹378.35 · Close at T+365 ₹502.30
- +32.8%Entry ₹378.35 · Close at T+365 ₹502.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Zydus Lifesciences Limited Hold (neutral), based on 29 analysts. Average price target: ₹1,210.29.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,074 of 26,286 companies
61.2
score / 100
Value44
Quality79
FCF yld-0.5%
Earn yld4.5%
EV/EBITDA14.9x
ROE18%
Gross mgn71%
Net mgn19%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹1,114.10
Analyst consensus
29 analystsHold
₹800.00Target ₹1,210.29(+9%)₹1,457.48
Income statement
Revenue₹267.2B
Gross profit₹190.6B71% margin
EBITDA₹83.9B31% margin
Net income₹50.4B15.8% margin
Valuation
PER (trailing)24.8x
PER (forward)22.6x
P/Book4.1x
Beta0.37
Balance sheet & cash
Market cap₹1.1T
Total debt₹125B
Free Cash Flow-₹5.5B
Debt / Equity42%
Profitability & ownership
ROE18.3%
ROA8.1%
% insiders75.2%
% institutions15.5%
Last declaration on 24 August 2026
Declarations96 total
32,577 shares0EquityOthersSEBI:ea9dcefd02e0bee760acd00e68263e8012946eb3
640 shares@ ₹1,260.000.0001% mcap100.0% of flowEquity SharesBuy BackSEBI:04aa948938aee392aab8cbeefb3ceea1e084d4f2
124 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:34d20d20e4c9bf7e74149f6c8758127af28adbea
124 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:9bdda33dd5c85e0b47e545ef1b62c34649747792
124 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:36e40d0d03bc2896d6674d30654fd7ce1adf1174
124 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:efc316965d351e329558c9ccdbf409f8a3e34a65
124 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:3f3020546a82a2915f7b58b1e1ae2d1ad93606a0
73 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:25a80295588a7d5a13fa7bc933e5b26d77aa422e
248 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:db712618e07e87493e477182f05c8355765ec8f1
149 shares@ ₹12,600.300.0002% mcap100.0% of flowEquity SharesBuy BackSEBI:2f1220dd9daf5502f95858f35e7d4f6df835232b
124 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:b7617fc62a06f22f7ad66f477aba4e7d13de51c7
98 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:a888fbabd52adbb808233e2d7ebf095fc2aca0e4
5 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:bd30e51b483f0d1e66e9174d728559579e7048fe
109 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:9adab773e88279a958584d9a4dc86e65f6f97e7a
209 shares@ ₹1,260.000.0000% mcap100.0% of flowEquity SharesBuy BackSEBI:3af32b44353453abd1342cc38d073ce273d98784
6,349,542 shares@ ₹1,260.000.74% mcap100.0% of flowEquity SharesBuy BackSEBI:118a730cb372a1a2c0bf3effba1bea74f078064c
10,000 shares0Equity SharesOff MarketSEBI:3177fd2efbc1476513435085ac9c7935208f2e06
1,000 shares@ ₹963.522100.0% of flowEquity SharesSEBI:e4c9983cad445dddcd36a51c902c60061dd60bfb
Canonical exit: 10 Feb 2026 (T+90)
10,000 shares@ ₹1,006.67551.6% of flowEquity SharesSEBI:b3facb9aefbc9b7ac34b3ca33b4b8fe8326744a5
292 shares@ ₹1,006.640410.4% of flowEquity SharesSEBI:f084c5e1280a5f936e24a6a81bbe585ac7c99387
30,000 shares@ ₹1,010.61944.8% of flowEquity SharesSEBI:cfcaf3f423b2b28861434fae2f825a0e396ebe63
292 shares@ ₹1,005.2510.4% of flowEquity SharesSEBI:0d1f28d530aa236354476c964eeeeeb666957d3a
17,534 shares@ ₹1,015.34772.8% of flowEquity SharesSEBI:e2c1f18ea620ac19daed7747cac15ffa1b8597a9
565,466 shares@ ₹1,008.658590.7% of flowEquity SharesSEBI:5c22120f18b9f1c212a3253d90cb63012e1a4f03
1,000 shares@ ₹1,009.074100.0% of flowEquity SharesSEBI:6cc46fa0dbaa4d39a66c9758dbed6dcd103b5497
25 of 96 declarations
About Zydus Lifesciences Limited
Zydus Lifesciences, an Indian pharmaceutical group listed on the Bombay stock exchange (INR 1,111.3 billion market capitalisation, 75.2% of the capital held by insiders), has a record of 96 filings between June 2, 2021 and August 24, 2026, from 51 filers. The largest trade is a sale by the Zydus Family Trust: EUR 6.3 million on March 27, 2024, followed by EUR 336,021 on March 28, 2024. The 13 sales total EUR 7.3 million, median EUR 69,333, against 6 purchases worth EUR 278,512, so 32% purchases.
The purchases cluster in late May 2022, in nearly identical amounts: EUR 67,439 for Desons Holdings and Finance Pvt. Limited and EUR 67,433 for Sheetal Rajan Navani on May 30, EUR 66,783 for Nitin Raojibhai Desai on May 26. Between May 26, 2022 and May 30, 2022, 4 insiders bought for EUR 269,120.
Read moreShow less
Deval Dhirajbhai Shah is the most frequent filer, with 7 filings including 3 sales; the Zydus Family Trust has 4, all sales. The record also holds 77 other filings. Yearly volume is 4 in 2021, 43 in 2022, 31 in 2024, 1 in 2025 and 17 in 2026. The 18 filings of the last twelve months include 1 purchase. Publication takes a median of 1 day.
